Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Company Overview

Elicio Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapies designed to activate and strengthen the immune system’s response to tumors. The company’s approach is based on its Amphiphile technology, which is intended to direct therapeutic agents to lymph nodes, where immune responses are initiated and expanded.

Elicio’s leading program, ELI-002, is an investigational therapeutic cancer vaccine targeting common KRAS mutations. The program is being studied in patients with certain solid tumors, including pancreatic and colorectal cancers, with the goal of treating minimal residual disease and reducing the risk of recurrence. The company is also advancing additional vaccine and immunotherapy programs based on its lymph-node-targeting platform.

Based in the United States, Elicio focuses on developing therapies for patients with cancer and works through clinical research and biotechnology partnerships. Its products remain investigational and are not approved for general commercial use.

Key Stats

• Today's Range: $1.84 to $1.90
• 50-Day Range: $1.77 to $3.20
• 52-Week Range: $1.71 to $16.00
• Volume: 195,352 shs
• Average Volume: 373,636 shs
• Market Capitalization: $49.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.75
• Consensus Rating: Moderate Buy

Elicio Therapeutics Stock Analysis - MarketRank™

Elicio Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 523rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Elicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Elicio Therapeutics has a consensus price target of $19.75, representing about 956.1% upside from its current price of $1.87.

Amount of Analyst Coverage

Elicio Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Elicio Therapeutics are expected to decrease in the coming year, from ($2.10) to ($2.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elicio Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elicio Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elicio Therapeutics has a P/B Ratio of 20.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.28% of the float of Elicio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Elicio Therapeutics has a short interest ratio ("days to cover") of 5.29.

Change versus previous month

Short interest in Elicio Therapeutics has recently decreased by 5.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elicio Therapeutics does not currently pay a dividend.

Dividend Growth

Elicio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Elicio Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Elicio Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ELTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.03% of the stock of Elicio Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELTX
• CIK: 1555192
• Web: www.angion.com
• Phone: 415-655-4899
• Fax: N/A
• Employees: N/A
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Elicio Therapeutics: $19.75
• High Price Target: $27.00
• Low Price Target: $12.00
• Potential Upside/Downside: +956.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,266.43%
• Return on Assets: -139.94%

Debt

• Debt-to-Equity Ratio: 1.20
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 20.78

Miscellaneous

• Outstanding Shares: 26,280,000
• Free Float: 12,904,000
• Market Cap: $49.14 million
• Optionable: Not Optionable
• Beta: 1.29